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Background
Anaphylaxis is a severe and life threatening hypersensi-
tivity reaction.
Individuals at risk can be offered an adrenaline auto-
injector to use in the event of an attack. The dose
required is dependent on the brand of adrenaline auto
injector and the weight of the patient as outlined in The
British National Formulary (BNF):
Anapen Over 30kg 0.3mg
Over 60kg 0.5mg
Epipen 15-30kg 0.15mg (Unlicensed for less than
15kg)
Over 30kg 0.3mg
Jext 15-30kg 0.15mg (Unlicensed for less than 15kg)
Over 30kg 0.3mg
For the adrenaline to be effective it is imperative that
the correct dose is administered.
Aim
To determine if patients at a general practice in East
London are being prescribed the correct dose of adrena-
line auto injector as outlined in the BNF.
Design: Using the computerised medical records sys-
tem patients using an adrenaline auto-injector over a 21
month period were identified. Following this, the latest
weight of the patient was identified and the dose of
adrenaline prescribed.
Results
25 patients were identified who had been prescribed an
adrenaline auto-injector. 11 of these had been prescribed
an Epipen Jr (0.15mg) and 14 the Epipen (0.3mg).
2 patients (both children) had been prescribed the
wrong dose for their weight. Of the remaining 9 patients
on an Epipen Jr (all children), 4 had not had a weight
recorded in the last year thus may potentially be on the
wrong dose.
Conclusion
Adrenaline auto-injector doses are weight dependent
and without weight monitoring the wrong dose can be
prescribed. This is particularly important in children
thus prescribers need to be aware of the need to moni-
tor their weight in anticipation of a need to increase the
dose. Measures should be put in place at general prac-
tices to promote awareness; recommendations include
local teaching and prompts on the electronic medical
records systems to remind prescribers to review the
dose.
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